Сцемблікс
(Асцімініб)
(40 mg)
(60 таб)
(Тат)
Сцемблікс / Scemblix (Asciminib / асцімініб) 40 мг 60 таб. Generic, Laos
In Stock
Indication
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with ≥2 tyrosine kinase inhibitors.6,9 It is also indicated in the treatment of Ph+ CML in adult patients with the T315I mutation.6
The drug is also indicated under accelerated approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
-
Commercial name:Сцемблікс
-
Сhemical name:Асцімініб
-
Dosage:40 mg
-
Quantity:60 таб
-
Release form:Тат
-
Производитель:Лаос
No reviews yet